Immunotherapy added to standard drugs may fight aggressive thyroid cancer

NCT ID NCT04238624

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether adding the immunotherapy drug cemiplimab to the usual combination of dabrafenib and trametinib can shrink tumors in people with a rare and aggressive form of thyroid cancer called anaplastic thyroid cancer. Participants have a specific genetic mutation (BRAF-V600E) and their cancer has stopped responding to the standard two-drug treatment. The goal is to see if the three-drug combination can control the disease better than the current approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (an immunotherapy antibody) added to dabrafenib and trametinib
What this could lead to: If it works, this could offer a new treatment option for people with a rare and aggressive thyroid cancer that has stopped responding to standard drugs.
What could go wrong: This is a small pilot study with only 16 participants, so results may not apply broadly. Immunotherapy can cause serious side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer thyroid gland undifferentiated (anaplastic) carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC THYROID CANCER BRAF GENE MUTATION BRAF MUTATION-RELATED TUMORS THYROID CANCER

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.